Key facts
- This page summarizes Atai Beckley N.V.'s Form 4 filing for IntelGenx Technologies Corp..
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 12 Mar 2024, 21:36.
Atai Beckley N.V. - 30 Sep 2023 Form 4 Insider Report for IntelGenx Technologies Corp.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 30 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2024, 21:36:30 UTC
- Prior SEC filing
- 05 Sep 2023
- Next SEC filing
- 03 May 2024
- Source filing
- View source filing
- Reporting owner signature
- ATAI Life Sciences N.V., By: /s/ Florian Brand, Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Atai Beckley N.V. filed Form 4 for IntelGenx Technologies Corp. on 12 Mar 2024.
Change
- Previous filing in this sequence was filed on 05 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IGXT
transaction
Derivative
Call Option (Right to Buy)
Other
- Transaction value
- Shares
- +7,401
- Change %
- Price
- Shares after
- 7,401
- Date
- 30 Sep 2023
- Ownership
- By ATAI Life Sciences AG
- Underlying class
- Units
- Underlying amount
- 7,401
- Exercise price
- Footnotes
- F1, F2, F3
IGXT
transaction
Derivative
Convertible Notes
Other
- Transaction value
- Shares
- +8,500,000
- Change %
- Price
- Shares after
- 8,500,000
- Date
- 06 Oct 2023
- Ownership
- By ATAI Life Sciences AG
- Underlying class
- Common Stock
- Underlying amount
- 56,435,098
- Exercise price
- $0.1850
- Footnotes
- F3, F4
IGXT
transaction
Derivative
Convertible Promissory Note
Purchase
- Transaction value
- Shares
- +750,000
- Change %
- +34%
- Price
- Shares after
- 2,970,000
- Date
- 28 Nov 2023
- Ownership
- By ATAI Life Sciences AG
- Underlying class
- Common Stock
- Underlying amount
- 4,054,054
- Exercise price
- $0.1850
- Footnotes
- F3, F5
IGXT
transaction
Derivative
Warrant (Right to Buy)
Purchase
- Transaction value
- Shares
- +4,053,750
- Change %
- +34%
- Price
- Shares after
- 16,052,850
- Date
- 28 Nov 2023
- Ownership
- By ATAI Life Sciences AG
- Underlying class
- Common Stock
- Underlying amount
- 4,053,750
- Exercise price
- $0.2600
- Footnotes
- F3, F5
IGXT
transaction
Derivative
Convertible Notes
Other
- Transaction value
- Shares
- +1,000,000
- Change %
- +12%
- Price
- Shares after
- 9,500,000
- Date
- 08 Mar 2024
- Ownership
- By ATAI Life Sciences AG
- Underlying class
- Common Stock
- Underlying amount
- 5,405,405
- Exercise price
- $0.1850
- Footnotes
- F3, F6
IGXT
transaction
Derivative
Warrant (Right to Buy)
Other
- Transaction value
- Shares
- +4,000,000
- Change %
- Price
- Shares after
- 4,000,000
- Date
- 08 Mar 2024
- Ownership
- By ATAI Life Sciences AG
- Underlying class
- Common Stock
- Underlying amount
- 4,000,000
- Exercise price
- $0.1700
- Footnotes
- F3, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Each unit consists of (a) one $1,000 principal amount convertible promissory note, convertible into shares of Common Stock at $0.185, and (b) 5,405 common stock purchase warrants, at a price of $0.26 per share, at any time prior to August 31, 2026.
Footnote F2
On September 30, 2023, ATAI AG entered into an amendment to a subscription agreement with the Issuer to provide ATAI AG with the right to purchase up to 7,401 additional units.
Footnote F3
Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.
Footnote F4
On September 30, 2023, the Issuer, IntelGenX Corp. and ATAI Life Sciences AG ("ATAI AG") entered into the Second Amended and Restated Loan Agreement, which provided, among other things, for the ability for ATAI AG to convert the $8,500,000 principal amount and accrued interest under the original term loan agreement into up to 56,435,098 shares of Common Stock at a price of $0.185 per share, subject to stock exchange approval, which was obtained on October 6, 2023.
Footnote F5
On November 28, 2023, ATAI AG purchased 750 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $750,000.
Footnote F6
On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the "Third Amendment"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration.